Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview

Journal of Neuroimmunology

Volumn 72, Issue 2, 1997, Pages 155-161

  Chandler, S ^a   Miller, K M ^a   Clements, J M ^a   Lury, J ^a   Corkill, D ^a   Anthony, D C C ^a   Adams, S E ^a   Gearing, A J H ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

matrix metalloproteinase; multiple sclerosis; tumor necrosis factor

Indexed keywords

MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR;

CONFERENCE PAPER; DEMYELINATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; HUMANS; METALLOENDOPEPTIDASES; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031040486     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00179-8     Document Type: Conference Paper

References (97)

1. Abramson, S. et al. (1995) Characterization of rat uterine matrilysin and its cDNA. J. Biol. Chem., 270, 16016-16022.
2. Aimes, R. and Quigley, J. (1995) Matrix metalloproteinase-2 is an interstitial collagenase: Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 270, 5872-5876.
3. Apodaca, G. et al. (1990) Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res. 50, 2322-2329.
4. Arribas, J. et al. (1996) Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 271(19), 11376-11382.
5. Baker, D. et al. (1994) Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24, 2040-4048.
6. Banda, M. et al. (1987) Interaction of mouse macrophage elastase with native and oxidised human alpha 1-proteinase inhibitor. J. Clin. Invest. 79, 1314-1317.
7. Beckett, R.P. et al. (1996) Recent advances in matrix metalloproteinase inhibitor research. DDT 1, 17-26.
8. Benvenuto, R. et al. (1991) Tumour necrosis factor alpha synthesis by cerebrospinal fluid-derived T cell clones from patients with multiple sclerosis. Clin. Exp. Immunol. 84, 97-102.
9. Birkedal-Hansen, H. et al. (1993) Matrix metalloproteinases: A review. Crit. Rev. Oral Biol. Med. 4, 197-250.
10. Calder, V. et al. (1989) MS: A localized immune disease of the central nervous system. Immunol. Today 10, 99-103.
11. Chandler, S. et al. (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 201, 223-226.
12. Chandler, S. et al. (1996) Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor alpha fusion protein. Biochem. Biophys. Res. Commun. 228, 421-429.
13. Clements, J. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J. Neuroimmunol., in press.
14. Conca, W. et al. (1994) Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis Rheum. 37, 951-956.
15. Corkill, D.J. et al. (1995) The effect of a novel inhibitor of tumour necrosis factor alpha processing, BB-1101, in experimental autoimmune encephalomyelitis. Br. J. Pharmacol., 8P.
16. Crabbe, T. et al. (1994a) Reciprocated matrix metalloproteinase activation: A process performed by interstitial collagenase and progelatinase A. Biochem. 33, 14419-14425.
17. Crabbe, T. et al. (1994b) Human progelatinase A can be activated by matrilysin. FEBS Lett. 345, 14-16.
18. Crowe, P.D. et al. (1994) A metalloprotease inhibitor blocks shedding of the 80 kDa TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 181, 1205-1210.
19. Cuzner, M.L. et al. (1978) Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann. Neurol. 4, 337-344.
20. 1-antichymotrypsin by oxidatively activated human neutrophil metalloproteinases. J. Biol. Chem. 267, 5005-5012.
21. Desrochers, D. et al. (1991) Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. J. Clin. Invest. 87, 2258-2265.
22. Docherty, A.J.P. et al. (1992) The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue diseases. TIBTECH. 10, 200-207.
23. Fosang, A. et al. (1993) Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem. J. 295, 273-276.
24. Fosang, A. et al. (1992) The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J. Biol. Chem. 267, 19470-19474.
25. 374 in the interglobular domain of cartilage aggrecan. Biochem. J. 304, 347-351.
26. Fosang, A. et al. (1991) Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J. Biol. Chem. 266, 15579-15582.
27. Fosang, A.J. et al. (1996) Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 380, 17-20.
28. Freije, J. et al. (1994) Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269, 16766-16773.
29. Fridman, R. et al. (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 55, 2548-2555.
30. Gearing, A.J.H. et al. (1994) Processing of tumour necrosis factor alpha precursor by metalloproteinases. Nature 370, 555-557.
31. Gijbels, K. et al. (1993) Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36, 432-440.
32. Gijbels, K. et al. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41, 29-34.
33. Gijbels, K. et al. (1994) Reversal of autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94, 2177-2182.
34. Hallpike, J.F. and Adams, C.W.M. (1969) Proteolysis and myelin breakdown - a review of recent histochemical and biochemical studies. Histochem. J. 1, 559-578.
35. Hewson, A.K. et al. (1995) Suppression of experimental allergic encephalomyelitis in the Lewis Rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44(8), 345-349.
36. Imai, K. et al. (1995) Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. J. Biol. Chem. 270, 6691-6697.
37. Inuzuka, T. et al. (1987) Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases. Acta Neurol. Scand. 76, 18-23.
38. Knäuper, V. et al. (1993a) Fragmentation of human polymorphonuclear-leucocyte collagenase. Biochem. J. 291, 847-854.
39. Knäuper, V. et al. (1993b) Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem. J. 295, 581-586.
40. Knäuper, V. et al. (1996a) Biochemical characterization of human collagenase-3. J. Biol. Chem. 271, 1544-1550.
41. Knäuper, V. et al. (1996b) Activation of human neutrophil procollagenase by stromelysin-2. J. Biol. Chem. 235, 187-191.
42. LePage, R. et al. (1995) Gelatinase A possesses a β-secretase-like activity in cleaving the amyoid protein precursor of Alzheimer's disease. FEBS Lett. 377, 267-270.
43. Leppert, D. et al. (1995) T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154, 4379-4389.
44. Maeda, A. et al. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55(3), 300-309.
45. 1-antichymotrypsin and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72 kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. 266, 15810-15816.
46. Matyszak, M.K. and Perry, V.H. (1995) Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Guérin. Neuroscience 64, 967-977.
47. Matyszak, M.K. and Perry, V.H.P. (1996) Inflammation induced breakdown of the BBB and demyelination are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol., in press.
48. Miller, K. et al. (1996) Increase in 92 kDa gelatinase in serum is associated with clinical relapse in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychol.
49. Miyazaki, K. et al. (1990) Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (Pump-1), secreted from human rectal carcinoma cell line. Cancer Res. 50, 7758-7764.
50. Miyazaki, K. et al. (1993) A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature 362, 839-841.
51. Miyazaki, K. et al. (1992) Activation of TIMP-2/progelatinase A complex by stromelysin. Biochem. Biophys. Res. Commun. 185, 852-859.
52. Moss, M.L. et al. (1997) Structural features and biochemical properties of TNF-α converting enzyme (TACE). J. Neuroimmunol. 72, 127-129.
53. Murphy, G. et al. (1987) Stromelysin is an activator of procollagenase: A study with natural and recombinant enzymes. Biochem. J. 248, 265-268.
54. Murphy, G. et al. (1991) Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysin-1 and -2 and punctuated metalloproteinase (PUMP). Biochem. J. 277, 277-279.
55. Murphy, G. et al. (1993) The 28 kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J. Biol. Chem. 268, 15435-15441.
56. Murphy, G. et al. (1982) Partial purification of collagenase and gelatinase from human polymorphonuclear leukocytes: Analyses of their actions on soluble and insoluble collagens. Biochem. J. 203, 209-221.
57. Nguyen, Q. et al. (1993) Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem. J. 295, 595-598.
58. Nicholson, R. et al. (1989) Human and rat malignant-tumor-associated mRNAs encode stromelysin-like metalloproteinases. Biochem. 28, 5195-5203.
59. Noël, A. et al. (1995) Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J. Biol. Chem. 270, 22866-22872.
60. Opdenakker, G. and Van Damme, J. (1994) Cytokine-regulated proteases in autoimmune diseases. Immunol. Today 15, 103-107.
61. Panchenko, M.V., Stetler-Stevenson, W.G., Trubetskoy, O.V., Gacheru, S.N. and Kagan, H.N. (1996) Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. J. Biol. Chem. 271, 7113-7119.
62. Pei, D. and Weiss, S. (1996) Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1process progelatinase A and express intrinsic matrix-degrading activity. J. Biol. Chem. 271, 9135-9140.
63. Pei, D. et al. (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 269, 25849-25855.
64. Perides, G. et al. (1995) Glial hyaluronate-binding protein: A product of metalloproteinase digestion of versican? Biochem. J. 312, 377-384.
65. Perry, V.H. and Linden, R. (1982) Evidence for dendritic competition in the developing retina. Nature 297, 683-685.
66. Preece, G. et al. (1996) Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J. Biol. Chem. 271, 11634-11640.
67. Rawlings, N.D. and Barrett, A.J. (1995) Evolutionary families of metallopeptidases. Methods Enzymol. 248, 183-228.
68. Roher, A. et al. (1994) Proteolysis of Aβ peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun. 205, 1755-1761.
69. Rosenberg, G.A. et al. (1992a) TIMP-2 reduces proteolytic opening of the blood-brain barrier by type IV collagenase. Brain Res. 576, 203-207.
70. Rosenberg, G.A. et al. (1992b) Tumour necrosis factor alpha induced gelatinase B causes delayed opening of the BBB: An expanded therapeutic window. Brain Res. 703, 151-155.
71. Sang, Q-X. et al. (1995) Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim. Biophys. Acta 1251, 99-108.
72. Sato, H. et al. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
73. Selmaj, K. et al. (1991) Identification of lymphotoxin and tumour necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87, 949-954.
74. Senior, R. et al. (1991) Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 266, 7870-7875.
75. Shapiro, S. et al. (1995) Activation of the 92 kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate: Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J. Biol. Chem. 270, 6351-6356.
76. Shapiro, S. et al. (1993) Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 268, 23824-23829
77. Sharief, M.K. and Thompson, E.J. (1992) In vivo relationship of tumour necrosis factor alpha to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38, 27-34.
78. Sires, U. et al. (1993) Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J. Biol. Chem. 268, 2069-2074; Mayer, U. et al. (1993) Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur. J. Biochem. 217, 877-884.
79. Sires, U. et al. (1993) Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J. Biol. Chem. 268, 2069-2074; Mayer, U. et al. (1993) Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur. J. Biochem. 217, 877-884.
80. 1-antitrypsin. Biochem. Biophys. Res. Commun. 204, 613-620.
81. Sires, U. et al. (1995a) Degradation of the COL1 domain of type XIV collagen by 92 kDa gelatinase. J. Biol. Chem. 270, 1062-1067.
82. Sires, U. et al. (1995b) Complete degradation of type X collagen requires the combined action of interstitial collagenase and osteoclast-derived cathepsin-B. J. Clin. Invest. 95, 2089-2095.
83. Sommer, N. et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1, 244-248.
84. Steinman, L. and Gijbels, K. (1994) Gelatinase B producing cells in multiple sclerosis lesions. J. Cell. Biochem. Suppl. 18D 143.
85. Takino, T. et al. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270, 23013-23020; (NB: this MT-MMP has been re-classified as MT-MMP-3 due to the prior publication of an MT-MMP-2 sequence by Will, H. and Hinzmann, B. (1995) cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 231, 602-608).
86. Takino, T. et al. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270, 23013-23020; (NB: this MT-MMP has been re-classified as MT-MMP-3 due to the prior publication of an MT-MMP-2 sequence by Will, H. and Hinzmann, B. (1995) cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 231, 602-608).
87. Tanaka, M. et al. (1996) Fas ligand in serum. Nat. Med. 2, 317-322.
88. Tschesche, H. et al. (1992) Latent collagenase and gelatinase from human neutrophils and their activation. Matrix Suppl. 1, 245-255.
89. von Bredow, D. et al. (1995) Degradation of fibronectin fibrils by matrilysin and characterization of the degradation products. Exp. Cell Res. 221, 83-91.
90. Welgus, H. et al. (1990a) Differential susceptibility of type X collagen to cleavage by two mammalian collagenases and 72 kD type IV collagenase. J. Biol. Chem. 265, 13521-13527.
91. Welgus, H.G. et al. (1990b) Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation and expression during cellular development. J. Clin. Invest. 86, 1496-502
92. Wells, G.M.A. et al. (1996) Quantitation of matrix metalloproteinases in cultured rat astrocytes using the polymerase chain reaction with a multi-competitor cDNA standard. Glia, in press.
93. Whitelock, J.M. et al. (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanase. J. Biol. Chem. 271, 10079-10086.
94. Windsor, L. et al. (1993) Cell type-specific regulation of SL-1 and SL-2 genes. Induction of the SL-2 gene but not the SL-1 gene by human keratinocytes in response to cytokines and phorbolesters. J. Biol. Chem. 268, 17341-17347.
95. Wolfsberg, T.G. et al. (1995) ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 131(2), 275-278.
96. Yamada, T. et al. (1995a) Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and Schwann cells. Acta Neuropathol. 89, 199-203.
97. Yamada, T. et al. (1995b) White matter microglia produce membrane-type matrix metalloproteinase, an activator of gelatinase A, in human brain tissue. Acta Neuropathol. 90, 421-424.